1739 related articles for article (PubMed ID: 19208563)
1. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
Garin MC; Highland KB; Silver RM; Strange C
J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
[TBL] [Abstract][Full Text] [Related]
3. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
[TBL] [Abstract][Full Text] [Related]
4. Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: are we counting what counts?
Pamidi S; Mehta S
J Rheumatol; 2009 Feb; 36(2):216-8. PubMed ID: 19208554
[No Abstract] [Full Text] [Related]
5. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
[TBL] [Abstract][Full Text] [Related]
6. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.
Beretta L; Santaniello A; Lemos A; Masciocchi M; Scorza R
Rheumatology (Oxford); 2007 Feb; 46(2):296-301. PubMed ID: 16877463
[TBL] [Abstract][Full Text] [Related]
7. Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension.
Andrade FM; Oliveira AD; Lopes AJ
Braz J Med Biol Res; 2019; 52(8):e8513. PubMed ID: 31365695
[TBL] [Abstract][Full Text] [Related]
8. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis.
Modrykamien AM; Gudavalli R; McCarthy K; Parambil J
Respir Care; 2010 May; 55(5):584-8. PubMed ID: 20420729
[TBL] [Abstract][Full Text] [Related]
9. [Peak oxygen uptake during the six-minute walk test in diffuse interstitial lung disease and pulmonary hypertension].
Blanco I; Villaquirán C; Valera JL; Molina-Molina M; Xaubet A; Rodríguez-Roisin R; Barberà JA; Roca J
Arch Bronconeumol; 2010 Mar; 46(3):122-8. PubMed ID: 20138698
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
11. Relationship between left ventricular diastolic dysfunction and six minute walk test in patients with systemic sclerosis.
Akdogan A; Kaya EB; Sahin A; Okutucu S; Yakut E; Kalyoncu U; Aksoy H; Karadag O; Calguneri M; Tokgozoglu L; Kiraz S; Ertenli I
Int J Rheum Dis; 2011 Oct; 14(4):379-83. PubMed ID: 22004236
[TBL] [Abstract][Full Text] [Related]
12. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease.
Holland AE; Hill CJ; Glaspole I; Goh N; McDonald CF
Respir Med; 2012 Mar; 106(3):429-35. PubMed ID: 22182340
[TBL] [Abstract][Full Text] [Related]
13. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
[TBL] [Abstract][Full Text] [Related]
14. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.
Buch MH; Denton CP; Furst DE; Guillevin L; Rubin LJ; Wells AU; Matucci-Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black CM; Seibold JR
Ann Rheum Dis; 2007 Feb; 66(2):169-73. PubMed ID: 16868020
[TBL] [Abstract][Full Text] [Related]
15. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.
Vandecasteele E; De Pauw M; De Keyser F; Decuman S; Deschepper E; Piette Y; Brusselle G; Smith V
Int J Cardiol; 2016 Jun; 212():265-73. PubMed ID: 27057932
[TBL] [Abstract][Full Text] [Related]
16. Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing.
Martis N; Queyrel-Moranne V; Launay D; Neviere R; Fuzibet JG; Marquette CH; Leroy S
J Rheumatol; 2018 Jan; 45(1):95-102. PubMed ID: 29093153
[TBL] [Abstract][Full Text] [Related]
17. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis.
Schoindre Y; Meune C; Dinh-Xuan AT; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Jul; 36(7):1481-5. PubMed ID: 19487260
[TBL] [Abstract][Full Text] [Related]
18. Association of six-minute walk distance (6MWD) with resting pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
Fujimoto H; Asai K; Watanabe T; Kanazawa H; Hirata K
Osaka City Med J; 2011 Jun; 57(1):21-9. PubMed ID: 22106764
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with the 6-minute walk distance in patients with systemic sclerosis.
Sanges S; Giovannelli J; Sobanski V; Morell-Dubois S; Maillard H; Lambert M; Podevin C; Lamblin N; De Groote P; Bervar JF; Perez T; Matran R; Rémy-Jardin M; Hatron PY; Hachulla É; Launay D
Arthritis Res Ther; 2017 Dec; 19(1):279. PubMed ID: 29246248
[TBL] [Abstract][Full Text] [Related]
20. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
